|
World Smoking-Cessation Drug Market 2010-2025
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
Highlights of the report include:Why you should buy World Smoking-Cessation Drug Market 2010-2025 This report gives you the following benefits in particular: • You will receive a comprehensive analysis of the prospects for smoking-cessation drugs from 2010 to 2025, including predicted revenues, growth rates and other key metrics • You will find out where the market is heading - both technologically and commercially - from the present onwards, both for the overall world market and for leading national markets • You will discover prospects for Chantix/Champix, in light of recent concerns • You will identify key pipeline developments and up-and-coming products • You will discover the drivers, restraints, competition and opportunities influencing the smoking-cessation market, including those for nicotine replacement therapies, Pfizer’s Chantix/Champix and bupropion drugs • You will receive expert views from our original unique interviews - unavailable anywhere else 123 seiten | |||||||||||
| Inhalt der Studie: |
Smoking is a leading cause of preventable death worldwide. In 2009, total sales of smoking-cessation products surpassed $1.6bn (Rx products). The effects of smoking constitute a major burden on public.....
Smoking is a leading cause of preventable death worldwide. In 2009, total sales of smoking-cessation products surpassed $1.6bn (Rx products). The effects of smoking constitute a major burden on public healthcare systems, as well as lowering quality of life for many people. Currently-marketed smoking-cessation products arguably lack the desired levels of efficacy in practice, with the reputation of some suffering through noted side-effects. As a result, there are significant commercial opportunities for more-efficacious and better-tolerated smoking-cessation agents, especially in prescription form. Our new report – World Smoking-Cessation Drug Market 2010-2025 – forecasts how the anti-smoking drug market will develop over the next 15 years. We predict that the launch of new smoking-cessation aids early this decade will answer some unmet needs currently limiting that pharma market segment. Besides extensive coverage of currently-marketed drugs, this report examines the most exciting products currently in development. We also include external opinions on the sector, gained thorough original unique surveys. Our report analyses current leading markets in North America, Europe and Asia in detail. A major contribution to the market during the next 15 years will come from emerging economies, led by India and China. Almost half of the world’s smokers live in those countries, with almost a third in China alone, reports suggest. At present, those national markets yield relatively low smoking-cessation revenues. However, visiongain predicts that the emerging economies have a large potential for sales growth of smoking-cessation products. This report reveals how their sales revenues and market shares will expand during the forecast period. The majority of smokers worldwide do not have full access to smoking-cessation therapies at present. The high economic and social costs associated with tobacco use are driving anti-smoking legislation and encouraging governmental spending on tobacco-dependency treatments. From 2010 to 2025, the implementation and expansion of tobacco-control policies – especially public smoking bans – will continue. Combined, those policies will help to increase the use of smoking-cessation products, agents still with a long way to go in their technological and commercial development, our report shows. Comprehensive analysis of the smoking-cessation pharmaceutical market World Smoking-Cessation Drug Market 2010-2025 critically examines that sector through a comprehensive review of primary and secondary information sources. Our new report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints. There are over 50 tables and figures included, as well as two interviews with relevant experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work. Our research shows that new smoking-cessation drugs should achieve commercial success if they are clearly tolerable and more effective in practice than existing products, easily accessible, backed by innovative marketing campaigns and delivered in combination with behavioural support programmes. Smoking-cessation drugs with those characteristics would have good overall prospects with regulators and healthcare providers. You can obtain this report today Nobody with an interest in the smoking-cessation market should overlook this new study. We predict that total revenues will increase over our forecast period, 2010 to 2025. With rising demand for products worldwide and currently-unmet needs, this therapeutic area holds significant potential for further revenue growth and technological innovation. Do you want to harness those opportunities? You can stay ahead by ordering this report today. Report Highlights Companies Listed: Action on Smoking on Health (ASH) [UK] American Heart Association (AHA) [US] American Lung Association (ALA) [US] Biotie Therapies [Finland] Biovail Boehringer Ingelheim Ceejay Healthcare Celtic Pharma Centers for Disease Control and Prevention (CDC) [US] Cytos Biotechnology European Medicines Agency (EMEA) Evotec Food and Drug Administration (FDA) [US] Georgetown University School of Medicine [US] GlaxoSmithKline (GSK) Greater Rochester Tobacco Research Center Independent Pharmaceutica Johnson & Johnson Karolinska Institutet [Sweden] Lundbeck Mayo Clinic [US] Medical College of Wisconsin Research Foundation [US] Medicines and Healthcare products Regulatory Agency (MHRA) [UK] Ministry of Health, Labour and Welfare (MHLW) [Japan] Mylan Nabi Biopharmaceuticals National Cancer Institute (NCI) [US] National Health Service (NHS) [UK] National Institute for Health and Clinical Excellence (NICE) [UK] National Institute of Drug Abuse (NIDA) [US] National Institutes of Health (NIH) [US] Novartis Perrigo Pfizer Pierre Fabre Ruyan Sanofi-Aventis Sigma The Smoking Research Program [US] Somaxon Sopharma Taisho Takeda Targacept Teva University of California [US] Watson World Health Organization (WHO) Zenara [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 2. Introduction to Smoking Cessation 2.1 Tobacco 2.1.1 Types of Tobacco Consumption 2.1.2 Tobacco Addiction is a Major Global Health Problem 2.2 Nicotine Addiction 2.3 Smoking Cessation 2.3.1 Why is it Difficult to Stop Smoking? 2.3.2 Methods for Smoking Cessation 3. Pharmacological Smoking-Cessation Products 3.1 Nicotine Replacement Therapy (NRT) 3.1.1 Nicorette NRT (Johnson & Johnson/Takeda) 3.1.2 Nicabate/NicoDerm/Nicorette/NiQuitin NRT Brands (GSK) 3.1.3 Novartis NRT Brands 3.1.4 Other NRT Manufacturers 3.2 Chantix/Champix (varenicline, Pfizer) 3.3 Bupropion 3.3.1 Zyban (GSK/Biovail) 3.3.2 Generic Bupropion Drugs 3.4 Off-Label Drug Prescribing for Smoking Cessation 4. The World Smoking-Cessation Market 4.1 The World Smoking-Cessation Market Value, 2008-2009 4.1.1 Smoking-Cessation Market Value 4.1.2 Leading Smoking-Cessation Product Types 4.1.3 Leading Smoking-Cessation Brands 4.1.4 Leading Smoking-Cessation Manufacturers 4.2 The World Smoking-Cessation Market Forecast, 2010-2025 4.2.1 Growth in the Smoking-Cessation Market, 2010-2025 4.2.2 Emerging Products and Sales Forecast of the Smoking-Cessation Market, 2010-2025 4.2.3 Smoking-Cessation Market from 2010-2020 4.2.4 Market Acceleration from 2020 to 2025 4.2.5 Smoking-Cessation Product Type Sales Forecast, 2010-2025 5. Individual Market Forecasts for Leading Drugs, 2010-2025 5.1 Nicotine Replacement Therapies Sales Forecast, 2010-2025 5.1.1 Individual NRT Sales Forecast, 2010-2025 5.1.2 Upper Level NRT Sales Forecast, 2010-2025 5.1.3 Lower Level NRT Sales Forecast, 2010-2025 5.2 Chantix/Champix Sales Forecast, 2010-2025 5.3 Bupropion Smoking-Cessation Drugs Sales Forecast, 2010-2025 6. Geographical Breakdown of the Smoking-Cessation Market, 2010-2025 6.1 The Leading Smoking-Cessation Markets 6.2 Leading Smoking-Cessation Country Markets and Sales Forecast, 2010-2025 6.3 The US Smoking-Cessation Market 6.3.1 Smoking Prevalence Declining in US 6.3.2 Availability and Reimbursement of Smoking-Cessation Aids in the US 6.3.3 US Smoking-Cessation Market Revenue, 2008-2009 6.3.4 Is there Scope for US Smoking-Cessation Market Expansion? 6.3.5 US Smoking-Cessation Market Forecast, 2010-2025 6.4 The UK Smoking-Cessation Market 6.4.1 Tobacco Use in the UK 6.4.2 The UK Pioneers Smoking-Cessation Reimbursement and OTC Retailing of NRT Products 6.4.3 The UK is Europe's Largest Smoking-Cessation Market 6.4.4 UK Government Anti-Smoking Legislation Lifts Market 6.4.5 UK Smoking-Cessation Market Forecast, 2010-2025 6.5 The Canadian Smoking-Cessation Market 6.5.1 Current Smoking Prevalence in Canada 6.5.2 Availability and Reimbursement of Smoking-Cessation Products in Canada 6.5.3 Factors Affecting the Canadian Smoking-Cessation Market 6.5.4 Canadian Smoking-Cessation Market Forecast, 2010-2025 6.6 The Japanese Smoking-Cessation Market 6.6.1 Japan has a Relatively Undeveloped Smoking-Cessation Market 6.6.2 The Japanese Smoking-Cessation Market, 2008-2010 6.6.3 Japanese Smoking-Cessation Market Forecast, 2010-2025 6.7 The French Smoking-Cessation Market 6.7.1 French Smoking Prevalence 6.7.2 The French Smoking-Cessation Market, 2008-2009 6.7.3 French Government's Provision of Smoking-Cessation Aids is Better than that in Many Other European Countries 6.7.4 French Smoking-Cessation Market Forecast, 2010-2025 6.8 The Swedish Smoking-Cessation Market 6.8.1 Snus in Sweden Increasing in Prevalence 6.8.2 The Swedish Smoking-Cessation Market in 2008-2009 6.8.3 Swedish Smoking-Cessation Market Forecast, 2010-2025 6.9 The Danish Smoking-Cessation Market 6.9.1 Smoking Prevalence Still High in Denmark 6.9.2 Danish Smoking-Cessation Market Forecast, 2010-2025 6.10 The German Smoking-Cessation Market 6.10.1 The German Smoking-Cessation Market, 2007-2008 6.10.2 Factors Holding Back the German Smoking-Cessation Market 6.10.3 German Smoking-Cessation Market Forecast, 2010-2025 7. Emerging Countries in the Smoking-Cessation Market 7.1 Greatest Market Growth Predicted in India and China 7.2 The Indian Smoking-Cessation Market 7.2.1 Tobacco in India is Both Smoked and Chewed 7.2.2 The Indian Smoking-Cessation Market, 2008-2009 7.2.3 Indian Smoking-Cessation Market Still in its Infancy 7.2.4 Prospects for Growth of the Indian Smoking-Cessation Market 7.2.5 Indian Smoking-Cessation Market Forecast, 2010-2025 7.3 The Chinese Smoking-Cessation Market 7.3.1 More than 5 Billion Cigarettes are Smoked in China Every Day 7.3.2 The Chinese Smoking-Cessation Market, 2008-2009 7.3.3 The Chinese Smoking-Cessation Market is Currently Undeveloped 7.3.4 Smoking-Cessation Market Prospects in China and Hong Kong 7.3.5 Chinese Smoking-Cessation Market Forecast, 2010-2025 8. Issues Affecting the Smoking-Cessation Market, 2010-2025 8.1 SWOT Analysis of the Global Smoking-Cessation Market 8.2 Strengths of the Smoking-Cessation Sector 8.2.1 Innovation in Smoking-Cessation Therapies 8.2.2 Innovative Marketing Techniques 8.2.3 Support Plans and Web 2.0 Technology in Combination with Pharmacotherapy 8.2.4 OTC-Switching 8.3 Weaknesses of the Smoking-Cessation Sector 8.3.1 Drugs Do Not Replace the Tactile and Oral Sensations Obtained from Smoking 8.3.2 Currently-Marketed Smoking-Cessation Therapies - Relapse Rate 8.4 Opportunities for the Smoking-Cessation Market 8.4.1 Smoking is Prevalent Worldwide and Slowly Increasing 8.4.2 Countries with Untapped Smoking-Cessation Market Potential 8.4.3 Growth of Emerging-Economy Smoking-Cessation Markets 8.4.4 Health Effects of Tobacco 8.4.5 Economic Impact of Tobacco Use 8.4.6 Framework Convention on Tobacco Control (FCTC) 8.4.7 Government-Sponsored Smoking-Cessation Programmes 8.4.8 Increasing Tobacco Taxes 8.4.9 Smoking Bans 8.4.10 Warning Information on Tobacco Products 8.4.11 Bans on Tobacco Advertising, Promotion and Sponsorship 8.5 Threats to the Smoking-Cessation Industry 8.5.1 Concern over Side-Effects of Smoking-Cessation Drugs 8.5.1.1 Champix/Chantix 8.5.1.2 Side-Effect Concerns for NRT and Bupropion 8.5.1.3 The Result of Side-Effect Concerns 8.5.2 Reimbursement for Smoking-Cessation Therapies 8.5.3 Traditional Smokeless Tobacco 8.5.3.1 Snus and Gutkha 8.5.3.2 Possible Impact of Greater Smokeless Tobacco Use 8.5.4 The E-Cigarette 8.5.4.1 The E-Cigarette Market 8.5.4.2 Will E-Cigarettes Revolutionise Tobacco Use and Pose a Threat to the Smoking-Cessation Market? 8.5.4.3 E-Cigarettes and Smoking-Cessation Therapies 9. Expert Interviews 9.1 Opinion on the Smoking-Cessation Sector from Dr Scott McIntosh, Director of the Greater Rochester Tobacco Research Center, USA, and Associate Director of the Smoking Research Program 9.1.1 Unmet Needs of the Smoking-Cessation Market 9.1.2 The Greatest Pharmacological Obstacles within the Smoking-Cessation Market 9.1.3 Drivers & Restraints of the Smoking-Cessation Market 9.1.4 Drugs and Smokeless Cigarettes 9.1.5 Are Vaccines More Effective than NRTs? 9.2 Opinion on Nicotine Vaccines from Dr Raafat Fahim, President and Chief Executive Officer, Nabi Biopharmaceuticals 9.2.1 Vaccines in the Pipeline for Nicotine Addiction 9.2.2 NicVAX Nicotine Vaccine 9.2.3 Other Nicotine Vaccines 10. The Smoking-Cessation Pipeline 10.1 Novel Vaccines Will Target Nicotine Addiction 10.1.1 NicVAX (Nabi Biopharmaceuticals) 10.1.2 TA-NIC (Celtic Pharma) 10.1.3 Niccine (Independent Pharmaceutica) 10.2 Monoamine Oxidase Inhibitors 10.2.1 EVT 302 (Evotec) 10.2.2 Selegiline (National Institute on Drug Abuse [NIDA]) 10.3 Glycine Antagonists 10.4 Opiate Antagonists and Agonists 10.5 Dopamine D3 Antagonists 10.6 Nicotinic Ligands 10.7 Dopamine Uptake Inhibitors 10.8 Cannabinoid Receptor 1 Antagonists 11. Conclusions 11.1 Smoking is One of the Gravest Threats to Health Worldwide 11.2 Smoking Cessation 11.3 The Smoking-Cessation Market in 2010 11.4 World Smoking-Cessation Market: Prospects from 2010 to 2025 11.5 Leading and Emerging Smoking-Cessation Markets 11.6 Concluding Thoughts on the Market [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 3.1 Nicotine Replacement Therapy Types, 2009 Table 3.2 Nicorette NRT Brands (Johnson & Johnson/Takeda), 2009 Table 3.3 Nicabate/NicoDerm/Nicorette/NiQuitin NRT Brands (GSK), 2009 Table 3.4 Novartis NRT Brands, 2009 Table 3.5 Other NRT Brands, 2009 Table 3.6 Key Drugs Prescribed Off-Label for Smoking Cessation, 2009 Table 4.1 World Smoking-Cessation Market: Sales, 2008-2009 Table 4.2 Leading Smoking-Cessation Product Types: Sales and Market Shares, 2008-2009 Table 4.3 Leading Smoking-Cessation Brands: Sales and Market Shares, 2009 Table 4.4 Leading Manufacturers of Smoking-Cessation Products: Sales and Market Shares, 2009 Table 4.5 World Smoking-Cessation Market: Sales Forecast, 2010-2016 Table 4.6 World Smoking-Cessation Market: Sales Forecast, 2017-2025 Table 4.7 Smoking-Cessation Product Type: Sales Forecasts, 2010-2016 Table 4.8 Smoking-Cessation Product Type: Sales Forecasts, 2017-2025 Table 5.1 Individual NRT Sales: Forecasts with Total Market, 2010-2016 Table 5.2 Individual NRT Sales: Forecasts with Total Market, 2017-2025 Table 6.1 Leading Smoking-Cessation Country Markets: Sales, 2009 Table 6.2 Smoking-Cessation Country Markets: Sales Forecasts, 2010-2016 Table 6.3 Smoking-Cessation Country Markets: Sales Forecasts, 2017-2025 Table 8.1 SWOT Analysis of the World Smoking-Cessation Market, 2010-2025 Table 10.1 Key Smoking-Cessation Pipeline Products, 2009 Table 11.1 Smoking-Cessation Country Markets: Sales Forecasts, Market Shares and CAGRs, 2009-2025 Figure 4.1 Leading Smoking-Cessation Product Types: Market Shares, 2009 Figure 4.2 Leading Smoking-Cessation Product Types: Market Shares, 2009 Figure 4.3 Leading Smoking-Cessation Brands: Market Shares, 2009 Figure 4.4 Leading Manufacturers of Smoking-Cessation Products: Market Shares, 2009 Figure 4.5 World Smoking-Cessation Market: Sales Forecast, 2010-2025 Figure 4.6 Product Type: Sales Forecast, 2010-2025 Figure 4.7 Product Type: Sales and Market Shares, 2008, 2010, 2015, 2025 Figure 5.1 NRT Market Sales: Forecast, 2010-2025 Figure 5.2 Upper Level NRT Individual Sales: Forecasts, 2010-2025 Figure 5.3 Lower Level NRT Individual Sales: Forecasts, 2010-2025 Figure 5.4 Individual NRT Market Shares, 2010 Figure 5.5 Individual NRT Market Shares, 2015 Figure 5.6 Individual NRT Market Shares, 2025 Figure 5.7 Chantix/Champix Sales Forecast, 2010-2025 Figure 5.8 Bupropion Sales Forecast, 2010-2025 Figure 6.1 Smoking-Cessation Market Shares by Country, 2009 Figure 6.2 Smoking-Cessation Market Shares by Country, 2010 Figure 6.3 Smoking-Cessation Market Shares by Country, 2015 Figure 6.4 Smoking-Cessation Market Shares by Country, 2025 Figure 6.5 US Smoking-Cessation Market: Sales Forecast, 2010-2025 Figure 6.6 UK Smoking-Cessation Market: Sales Forecast, 2010-2025 Figure 6.7 Canadian Smoking-Cessation Market: Sales Forecast, 2010-2025 Figure 6.8 Japanese Smoking-Cessation Market: Sales Forecast, 2010-2025 Figure 6.9 French Smoking-Cessation Market: Sales Forecast, 2010-2025 Figure 6.10 Swedish Smoking-Cessation Market: Sales Forecast, 2010-2025 Figure 6.11 Danish Smoking-Cessation Market: Sales Forecast, 2010-2025 Figure 6.12 German Smoking-Cessation Market: Sales Forecast, 2010-2025 Figure 7.1 World Smoking-Cessation Markets: CAGRs, 2009-2025 Figure 7.2 Indian Smoking-Cessation Market: Sales Forecast, 2010-2025 Figure 7.3 Chinese Smoking-Cessation Market: Sales Forecast, 2010-2025 Figure 11.1 World Smoking-Cessation Market: Sales Forecast, 2010-2025 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
